bf/NASDAQ:ALT_icon.jpeg

COM:ALTIMMUNE

Altimmune, Inc.

  • Stock

Last Close

7.35

12/11 21:00

Market Cap

530.35M

Beta: -

Volume Today

18.43M

Avg: -

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcel...Show More

peer of